Results 1 to 10 of about 17,302 (216)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia [PDF]

open access: yesHaematologica, 2023
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary.
Jonathan A. Gutman   +22 more
doaj   +2 more sources

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia [PDF]

open access: yesHaematologica, 2019
Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes.
Melita Kenealy   +15 more
doaj   +2 more sources

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML [PDF]

open access: yesAnnals of Hematology
Background Oral azacitidine improves survival in patients with AML in first complete remission who are not candidates for allogeneic transplantation. Most favorable-risk AML patients harbor molecular markers enabling sensitive measurable residual disease
Noa Hurvitz   +14 more
doaj   +2 more sources

Theoretical investigation of fullerene nano carrier anti-cancer drug delivery of Azacitidine [PDF]

open access: yesNanochemistry Research, 2023
Azacitidine, known under the brand Vidaza, has therapeutic applications for several health complications, including myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia.
Niloofar Jafari   +2 more
doaj   +1 more source

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens

open access: yesHaematologica, 2022
Time at home is a critically important outcome to adults with acute myeloid leukemia (AML) when selecting treatment; however, no study to date has adequately described the amount of time older adults spend at home following initiation of chemotherapy ...
Christopher E. Jensen   +7 more
doaj   +1 more source

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

open access: yesJournal of Hematology & Oncology, 2021
Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal.
Farhad Ravandi   +21 more
doaj   +1 more source

The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma

open access: yesHaematologica, 2008
Background Azacitidine is a DNA methyltransferase inhibitor and cytotoxic agent known to induce apoptosis of some cancer cells. This study evaluated the pre-clinical potential of azacitidine as a therapeutic agent for multiple myeloma.Design and Methods ...
Tiffany Khong   +2 more
doaj   +1 more source

Preventive Use of Azacitidine in Patients with Acute Myeloid Leukemia after Haploidentical Allo-BMT

open access: yesКлиническая онкогематология, 2019
Background. Haploidentical bone marrow transplantation (BMT) can be a reliable alternative if a fully matched donor is not available. The main challenges after BMT are a relapse of major disease, graft-versus-host disease (GVHD), and infections ...
R. Sh. Badaev   +7 more
doaj   +1 more source

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

open access: yesHaematologica, 2022
Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS).
Theodoros Karantanos   +17 more
doaj   +1 more source

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

open access: yesHaematologica, 2016
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well
Sylvain Thépot   +23 more
doaj   +1 more source

Home - About - Disclaimer - Privacy